Our vision of new therapeutic options for viral diseases
We are developing a drug candidate against viral diseases. benfovir focuses on an active ingredient that inhibits sugar and lipid metabolism, thereby preventing the generation of the crucial building blocks for virus formation and avoiding the overreaction of the immune system.
Where We Are At
We have finished the experimental part of the clinical phase I study assessing the safety, tolerability and pharmacokinetics of our drug candidate in healthy volunteers.
We are planning a clinical phase II study to evaluate the efficacy of our drug candidate in various viral diseases.
benfovir AG. October 11st, 2022
benfovir AG completed the first part of the Phase 1 trial testing transketolase inhibitor benfo-oxythiamine (B-OT)
benfovir AG announced that the first part of the Phase 1 clinical trial
(BV-01-101/ EudraCT Number: 2021-005616-60.) designed to evaluate the safety, tolerability, and pharmacokinetics of B-OT in healthy human volunteers has been successfully completed.
benfovir AG. June 1st, 2022
benfovir Announces First Subjects Dosed in Phase 1 Clinical Trial of B-OT
benfovir AG has reached another major milestone by moving its first compound into clinical development with the start of a Phase 1 testing B-OT in healthy volunteers.
benfovir AG, December 10th, 2021
New therapeutic approach against SARSCoV-2 successfully tested
Scientists at the Universities of Frankfurt a.M. and Kent (UK) have identified a metabolic pathway (pentose-phosphate pathway) that is crucial for the propagation of the SARSCoV- 2 virus in human cells. The compound benfo-oxythiamine, an inhibitor of this metabolic pathway, has succeeded in blocking the replication of the SARS-CoV-2 virus in human cells.
Do you have questions, are you interested in our clinical studies or would you like to participate in the further development of the inhibitor? Please contact us!